1. $EDAP EDAP TMS SA $EDAP ~ BUY ~ 5 Day Price Target: $3.75 Issued 04/10/2015 By Stock Price Target http://stockpricetarget.blogspot.com/2015/04/edap-tms-sa-edap-buy-5-day-price-target.html

  2. $EDAP H.C. Wainwright Reiterates Buy on Edap Tms SA (ADR) Following 4Q:14 Update http://www.smarteranalyst.com/2015/04/06/h-c-wainwright-reiterates-buy-edap-tms-sa-adr-following-4q14-update/

  3. $EDAP now that the ER is behind us, it s time for the run in to the FDA approval to begin.

  4. Annual and transition report of foreign private issuers [Sections 13 or 15(d)] http://www.conferencecalltranscripts.org/no/summary2/?id=1590089 $EDAP

  5. $EDAP: New SEC Filing for EDAP: Form IRANNOTICE, No. 0001171843-15-001793 http://stocknewsflow.com/1041934_000117184315001793_0001171843-15-001793

  6. Worth checking out notes suggested in $EDAP conference transcript http://www.conferencecalltranscripts.org/include/?location=http://seekingalpha.com/article/3048046-edap-tms-edap-ceo-marc-oczachowski-on-q4-2014-results-earnings-call-transcript

  7. $EDAP 4Q14 Q&A – Jon, Low Tide: Putting comparative data on InSightec? CEO: We take note of you comment.

  8. $EDAP 4Q14 Q&A – Jon, Low Tide: Am I correct that per treatment price for focal devices is EUR700-800? CEO: Is around EUR800-900.

  9. $EDAP 4Q14 Q&A – RK, H.C: HIFU for liver cancer? CEO: That’s still in the research project, now we are moving into new and advance phases.

  10. $EDAP 4Q14 Q&A – RK, H.C: How is De Novo different from PMA? CEO: It’s all explained in the FDA’s website.

  11. $EDAP 4Q14 Q&A – RK, H.C: 510k Application new data? CEO: We don’t need to start any new clinical study to provide new data.

  12. $EDAP 4Q14 Call – Eric, CFO: FY14 total revenue $35.4MM, up 11.2% vs. $32MM in FY13 and net loss was $676,000 vs. $6.7MM in FY13.

  13. $EDAP 4Q14 Call – Eric, CFO: Gross profit $3MM vs. $4.4MM in 4Q13. Gross profit margin on net sales was 37.3% vs. 40.1% in 4Q13.

  14. $EDAP 4Q14 Call – Marc, CEO: The record revenues we generated for FY14 were driven by 70% growth in revenue from HIFU division over 2013.

  15. $EDAP 4Q14 Call – Marc, CEO: Filing Direct De Novo petition for Ablatherm HIFU per FDA discussions. This is a huge opportunity for ECAP.

  16. $EDAP 4Q14 Call – Marc, CEO: After discussions on HIFU, the FDA suggested to consider seeking tool claim instead of disease treatment claim.

  17. $EDAP 4Q14 Call – Philippe, Chairman: In 2014, significantly increased HIFU revenue performance and further closed discussions with the FDA.

  18. $EDAP 4Q14 Call Participants: Philippe Chauveau, Chairman; Marc Oczachowski, CEO; and Eric Soyer, CFO.

  19. $EDAP 4Q14 PR: Record revenue in 2014 of $35.4MM, up 11% over previous year. Strong cash position of $14.7MM as of Dec. 31, 2014.

  20. $EDAP 4Q14 PR: Divisional Revenues: HIFU $1.3MM vs. $2.1MM in 4Q13; lithotripsy $6.7MM vs. $8.9MM in 4Q13.

  21. $EDAP 4Q14 PR: Net loss per diluted share $0.13 vs. $0.04 in 4Q13. OpEx $4.3MM vs. $4.1MM in 4Q13.

  22. $EDAP 4Q14 PR: Total revenue $8MM vs. $11MM in 4Q13. Net loss $3.3MM vs. $0.77MM in 4Q13.

  23. Listen to $EDAP Q4 2014 earnings call - live at 08:30 AM, ondemand after - http://earningscast.com/q1-2015-edap-tms-sa-earnings-conference-call

  24. stuffit: $EDAP TMS SA ($EDAP -0.8%) Q4 results: Revenues: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112349943

  25. $EDAP Earnings out BMO EPS Estimate -0.01